Introduction {#s1}
============

Esophageal cancer is considered one of the most aggressive cancers in the world. It includes two main types: esophageal adenocarcinoma (EADC) and esophageal squamous cell carcinoma (ESCC) [@pone.0100055-Vizcaino1]. ESCC is the predominant type of esophageal cancer in the East Asian population [@pone.0100055-Hongo1]. Epidemiological studies indicate that unhealthy lifestyles, including smoking tobacco and drinking alcohol, are major risk factors for esophageal cancer. However, only a subset of individuals would develop esophageal cancer under the environmental risk factors. This suggests the role of risk factors and genetic alterations in esophageal cancer carcinogenesis through gene-environment interactions. A series of single nucleotide polymorphisms (SNPs) were found to be associated with the risk of ESCC in studies with different designs and populations, and results were not consistency. It indicated that the genetic etiology of ESCC is complicated, and further independent investigation is needed to confirm the associations with ESCC risk.

MicroRNAs (miRNAs) are small endogenous 19--25 nucleotide (nt) non-coding RNAs that regulate gene expression by base pairing with target mRNAs at the 3-untranslated region, leading to mRNA cleavage or translational repression [@pone.0100055-Lee1], [@pone.0100055-Farh1]. By bioinformatic method, a single miRNA is predicted to bind to a large number of mRNA targets [@pone.0100055-Zamore1]. MiRNAs have been suggested to regulate almost one-third of human genes and most cancer-linked genes [@pone.0100055-Lewis1]. The biogenesis of miRNA proceeds as follows: a miRNA gene is transcribed into a primary miRNA (pri-miRNA) covering several hundred or thousand nucleotides in length [@pone.0100055-Bracht1], [@pone.0100055-Cai1]. The pri-miRNA then becomes a precursor miRNA (pre-miRNA) of 60--70 nt in length [@pone.0100055-Gregory1], [@pone.0100055-Han1]. Finally, the pre-miRNA is processed to a mature miRNA in length of 21--25 nt [@pone.0100055-Hutvagner1], [@pone.0100055-Ketting1].

SNPs or mutations in miRNA genes can influence the processing and/or target binding of miRNAs, thus resulting in diverse functional consequences and thereby possibly representing potential candidate biomarkers for cancer prognosis [@pone.0100055-Zhu1]--[@pone.0100055-Hu1]. MiR-124, including miR-124-1, functions as suppressors of hepatocellular carcinoma, hematological malignancies, cervical cancer and gastric cancer [@pone.0100055-Furuta1]--[@pone.0100055-Xia1]. Recently, rs531564 with a G/C variation was identified in pri-miR-124-1. This G/C variant has been reported to affect the expression of mature miR-124 in the central nervous system [@pone.0100055-Qi1]. This SNP was found associated with risks of gastric cancer, bladder cancer, and esophageal adenocarcinoma [@pone.0100055-Zhou1]--[@pone.0100055-Yang1]. Apart from this microRNA, there are many other microRNAs that have been identified as functional factors in cancer generation. For example, on the one hand, rs4938723/pri-miR-34b/c is associated with a significantly increased risk of hepatocellular carcinoma [@pone.0100055-Xu1], while on the other hand, it significantly decreased the risk of colorectal cancer [@pone.0100055-Gao1]. Rs895819/pre-miR-27a is associated with a significantly reduced risk of renal cell cancer [@pone.0100055-Shi1]. Rs7372209/pri-miR-26a-1 decreased bladder cancer risk in women [@pone.0100055-Yang1], and rs11134527/pri-miR-218 is associated with a significantly decreased risk of cervical carcinoma [@pone.0100055-Shi2], [@pone.0100055-Zhou2]. On the basis of the biological and pathologic significance of miRNA, it is possible that functional genetic variations in the pre/pri-miRNAs may contribute to the development of ESCC.

There were some studies related to these SNPs and cancer risks. However, whether these genetic variants of miRNA-related genes have an influence on the risk of ESCC has largely remained unknown. We have conducted a case-control study to investigate the potential association between rs531564/pri-miR-124-1, rs4938723/pri-miR-34b/c, rs7372209/pri-miR-26a-1, rs895819/pre-miR-27a, rs11134527/pri-miR-218 and the risk of ESCC.

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

The study was approved by the Institutional Review Board of the School of Life Sciences of Fudan University. Moreover, all participants had signed a written informed consent for donating their biological samples.

Study Population {#s2b}
----------------

These cases (age range = 37--88 years) were newly diagnosed patients, with histologically confirmed ESCC. All cases were recruited from two hospitals in eastern China: Taizhou People's Hospital and Shanghai Cancer Hospital between June 2009 and September 2011. There were no age, sex, ethnicity, or cancer stage restrictions on recruitment. Informed consent was provided to the patients who had been diagnosed in these hospitals during this period. Patients who agreed to the investigation were asked to fill the questionnaire.

All controls were recruited from the Taizhou Longitudinal study conducted in Taizhou City, eastern China during the same period as cases [@pone.0100055-Wang1]. The control subjects had no history of cancer and were divided in groups according to their age and sex (we take five years as a gap for division of groups). The controls are matched in frequency with the case group.

All participants were interviewed with a structured questionnaire in order to obtain demographic information, including age and sex. Data on alcohol consumption and smoking status were also collected. After the interview, 5 mL venous blood sample was collected from each participant.

For quality control of the samples, we checked the questionnaire, the clinical information of cases and the blood sample carefully. The samples that did not match the criteria were excluded (i.e. wrongly classified esophageal cancer type, blood sample missing, etc.).

Finally, this case-control study was composed of 1109 ESCC patients of Han Chinese and 1275 unrelated cancer-free control subjects with matched age, sex and ethnics.

SNP Selection and Genotyping {#s2c}
----------------------------

Candidate SNPs were selected based on a literature review of pri/pre-miRNA epidemiological studies [@pone.0100055-Qi1], [@pone.0100055-Zhou1], [@pone.0100055-Makeyev1]--[@pone.0100055-Toyota1]. A literature search was taken in the PubMed database. All papers reporting the association between the SNPs of miRNA genes and cancer risks were retrieved. Considering that ESCC is a type of esophageal carcinoma, as well as of squamous cell carcinoma, we have examined all the papers related to other types of esophageal carcinoma (i.e. EADC) or squamous cell carcinoma (i.e. cervical cancer) apart from ESCC. The SNPs that were already identified with clear relationship of ESCC risks were excluded. Finally, we selected these 5 candidate SNPs in our study, which are rs531564 in pri-miR-124-1, rs4938723 in pri-miR-34b/c, rs7372209 in pri-miR-26a-1, rs895819 in pre-miR-27a, and rs11134527 in pri-miR-218.

Genomic DNA was extracted from peripheral blood samples with a salt precipitation method. Genotyping was detected with a SNaPshot Multiplex System for single nucleotide extension. Loci of the above SNPs were first amplified by PCR. The PCR products were treated with SAP and ExoI to remove primers and unincorporated dNTPs, followed by ddNTP extension (SNaPshot) and fragment analysis. All primers are shown in [Table S1](#pone.0100055.s001){ref-type="supplementary-material"}. Results were analyzed by the Peak scanner version 1.0 (Applied Biosystems).

For the quality control of the genotyping, 5% of samples were selected randomly as replicates, and the reproducibility was 100%.

Statistical Analysis {#s2d}
--------------------

Differences in selected variables and Hardy-Weinberg equilibrium were evaluated using the Chi-square test and Student's t test as appropriate. Differences in the distributions of demographic characteristics and frequencies of genotypes between patients and control subjects were evaluated using Student's t test (for continuous variables) or Pearson's Chi-square test (for categorical variables).

The following genetic models were used in the analysis procedure: the dominant model (AA vs AB+BB), the recessive model (AA+AB vs BB), the codominant model (AA vs AB & AA vs BB) and the overdominant model (AA+BB vs AB); all models assuming B is the risk allele.

The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by univariate and multivariate logistic regression analyses to determine associations between rs531564/pri-miR-124-1, rs4938723/pri-miR-34b/c, rs7372209/pri-miR-26a-1, rs895819/pre-miR-27a, rs11134527/pri-miR-218 genotypes and the risk of ESCC. Adjusted ORs were computed using unconditional logistic regression with adjustment for age, sex, smoking, and drinking. A p-value less than 0.05 was considered statistically significant. The statistical analyses above were performed with the SPSS Software version 12.0 (SPSS, Chicago, IL, USA) and were based on two-tailed probability.

To investigate the combined contributions of genetic and non-genetic (such as smoking and drinking) factors involved in ESCC risk, we also performed the multifactor dimensionality reduction (MDR) analysis. This method was performed by MDR V2.0 software. (<http://www.multifactordimensionalityreduction.org>).

Results {#s3}
=======

Characteristics of the Study Population {#s3a}
---------------------------------------

Among all the ESCC patients invited in these hospitals, approximately 90% of them are involved in this investigation. As shown in [Table 1](#pone-0100055-t001){ref-type="table"}, the final analysis included 1109 ESCC patients and 1275 control subjects. No significant difference in age (p = 0.564) and sex (p = 0.229) was detected between case and control subjects, which shows that the frequency matching was adequate. However, higher rates of smokers and drinkers were identified in case subjects than in controls (p\<0.001).

10.1371/journal.pone.0100055.t001

###### Characteristics of case and control subjects.

![](pone.0100055.t001){#pone-0100055-t001-1}

  Characters       Case (n = 1109)   Control (n = 1275)     p[a](#nt101){ref-type="table-fn"}           
  --------------- ----------------- -------------------- --------------------------------------- ------ -------------
  Age (years)                                                                                               0.564
  ~\<~62                 520                46.9                           582                    45.6  
  ~≥~62                  589                53.1                           693                    54.4  
  Age (mean±SD)      62.77±8.98          63.50±8.96       0.076[b](#nt102){ref-type="table-fn"}         
  Sex                                                                                                       0.229
  Male                   857                77.3                           958                    75.1  
  Female                 252                22.7                           317                    24.9  
  Smoking                                                                                                \<**0.001**
  Yes                    721                65.0                           687                    53.9  
  No                     388                35.0                           588                    46.1  
  Drinking                                                                                               \<**0.001**
  Yes                    570                51.4                           435                    34.1  
  No                     539                48.6                           840                    65.9  

Two-sided ^2^ test.

Mann-Whitney U test.

[Table 2](#pone-0100055-t002){ref-type="table"} showed the allelic and genotype distributions of individual SNPs in the case and the control subjects. The observed frequencies for those polymorphisms were in agreement with the frequencies expected under Hardy--Weinberg equilibrium (p\>0.05 for each). The genotype frequencies of pri-miR-124-1 rs531564 C\>G were 72.4% (CC), 26.6% (CG), and 1.0% (GG) in the cases and 71.4% (CC), 26.0% (CG), and 2.6% (GG) in the controls, respectively; and the difference was statistically significant (p = 0.011). [Table 3](#pone-0100055-t003){ref-type="table"} showed the main effect of these SNPs and ESCC risks based on different genetic models. In the recessive model, we found that the GG genotype of rs531564 was revealed to decrease the risk of ESCC (GG VS. CC/CG, p = 0.005, OR = 0.61, 95% CI = 0.43--0.86). As the number of GG genotype is a bit small, we also take a Fisher's Exact Test and the result is still significant (p = 0.002). In the dominant model, no significant relationship between this SNP and ESCC risk was found (GG/CG VS. CC, p = 0.477, OR = 0.94, 95% CI = 0.78--1.12).

10.1371/journal.pone.0100055.t002

###### Genotyping results of the candidate SNPs.

![](pone.0100055.t002){#pone-0100055-t002-2}

                           location       Genotype   Cases (n = 1109 )   Controls (n = 1275 )   OR (95% CI)[a](#nt103){ref-type="table-fn"}    p     p~HWE~ of control                                               
  -------------------- ----------------- ---------- ------------------- ---------------------- --------------------------------------------- ------ ------------------- -------------------------------------------- -------
  miR-124-1 rs531564     primary-miRNA       CC             803                  72.4                               910                       71.4           1           **0.011** [b](#nt104){ref-type="table-fn"}   0.840
                                             CG             295                  26.6                               331                       26.0   0.99 (0.83, 1.20)                     0.952                     
                                             GG             11                   1.0                                34                        2.6    0.61 (0.43, 0.87)                   **0.005**                   
  miR-34 rs4938723       primary-miRNA       TT             489                  44.1                               569                       44.6           1           **0.033** [b](#nt104){ref-type="table-fn"}   0.816
                                             TC             536                  48.3                               573                       44.9   1.10 (0.93, 1.31)                     0.276                     
                                             CC             84                   7.6                                133                       10.5   0.84 (0.72, 0.98)                   **0.023**                   
  miR-26-1 rs7372209     primary-miRNA       GG             541                  48.8                               628                       49.3           1             0.341[b](#nt104){ref-type="table-fn"}      0.919
                                             GA             454                  40.9                               538                       42.2   0.98 (0.83, 1.17)                     0.888                     
                                             AA             114                  10.3                               109                       8.5    1.10 (0.95, 1.28)                     0.186                     
  miR-27 rs895819       precursor-miRNA      AA             613                  55.3                               719                       56.4           1             0.851[b](#nt104){ref-type="table-fn"}      0.481
                                             AG             414                  37.3                               466                       36.5   1.03 (0.87, 1.23)                     0.724                     
                                             GG             82                   7.4                                90                        7.1    1.04 (0.89, 1.23)                     0.625                     
  miR-218 rs11134527     primary-miRNA       TT             396                  35.7                               454                       35.6           1             0.512[b](#nt104){ref-type="table-fn"}      0.517
                                             TC             529                  47.7                               630                       49.4   0.94 (0.78, 1.12)                     0.491                     
                                             CC             184                  16.6                               191                       15.0   1.06 (0.93, 1.20)                     0.382                     

Adjusted for age, sex, drinking and smoking.

Chi-square test for 3 genotypes between case and control groups.

10.1371/journal.pone.0100055.t003

###### Association analyses of the candidate SNPs with ESCC risk.
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                              MAF    Dominant       Recessive       Overdominant                                                      
  ------------------------- ------- ---------- ------------------- -------------- ------------------- ----------- ------------------- -------
  miR-124-1 rs531564 C\>G    0.143    0.156     0.94 (0.78, 1.12)      0.477       0.61 (0.43, 0.86)   **0.005**   1.02 (0.84, 1.22)   0.867
  miR-34 rs4938723 T\>C      0.317    0.329     1.02 (0.87, 1.21)      0.780       0.82 (0.71, 0.95)   **0.007**   1.17 (0.99, 1.38)   0.066
  miR-26-1 rs7372209 G\>A    0.307    0.296     1.03 (0.87, 1.21)      0.743       1.11 (0.96, 1.27)     0.158     0.96 (0.81, 1.13)   0.615
  miR-27 rs895819 A\>G       0.261    0.253     1.04 (0.88, 1.23)      0.642       1.03 (0.88, 1.21)     0.707     1.02 (0.86, 1.21)   0.782
  miR-218 rs11134527 T\>C    0.404    0.397     0.98 (0.83, 1.16)      0.829       1.08 (0.97, 1.21)     0.170     0.90 (0.77, 1.07)   0.228

Adjusted for age, sex, drinking and smoking.

The genotype frequencies of pri-miR-34b/c rs4938723 T\>C for TT, TC and CC were 44.1%, 48.3% and 7.6% in the cases and 44.6%, 44.9% and 10.5% in the controls respectively. There was a significant difference (p = 0.033) between the cases and the controls. In the recessive model, the CC genotype was found associated with the decreased risk for ESCC (CC VS. TT/TC: p = 0.007, OR = 0.82, 95% CI = 0.71--0.95). Fisher's Exact Test also indicates the significant result (p = 0.018). In dominant model, however, no significant result was found (CC/TC VS. TT: p = 0.780, OR = 1.02, 95% CI = 0.87--1.21).

However, other polymorphisms, pri-miR-26-1 rs7372209 G\>A, pre-miR-27a rs895819 A\>G and pri-miR-218 rs11134527 T\>C, did not demonstrate any associations with the risk of ESCC in the codominant, dominant, recessive or overdominant models.

Stratification Analyses of Pri-miR-124-1 rs531564 C\>G, Pri-miR-34b/c rs4938723 T\>C and the Risk of ESCC {#s3b}
---------------------------------------------------------------------------------------------------------

To further evaluate the associations between pri-miR-124-1 rs531564 C\>G, pri-miR-34b/c rs4938723 T\>C and ESCC risk, respectively, we performed the stratification analyses in the recessive model according to age, sex, smoking and drinking ([Table 4](#pone-0100055-t004){ref-type="table"} and [Table 5](#pone-0100055-t005){ref-type="table"}).

10.1371/journal.pone.0100055.t004

###### Stratified results for pri-miR-124-1 rs531564 C\>G by age, sex, drinking and smoking.
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  Variable    GG vs. CC+CG   Crude OR (95% CI)           p           Adjust OR (95% CI)[a](#nt106){ref-type="table-fn"}           p          
  ---------- -------------- ------------------- ------------------- ---------------------------------------------------- ------------------- -----------
  Age                                                                                                                                        
  \<62           6/514            12/570         0.55 (0.21, 1.49)                         0.341                          0.76 (0.46, 1.25)     0.278
  ≥62            5/584            22/671         0.26 (0.10, 0.69)                         0.005                          0.52 (0.32, 0.86)   **0.010**
  Sex                                                                                                                                        
  Males          10/847           23/935         0.48 (0.23, 1.01)                         0.054                          0.70 (0.48, 1.02)     0.062
  Females        1/251            11/306         0.11 (0.01, 0.86)                         0.015                          0.36 (0.13, 1.01)     0.051
  Drinking                                                                                                                                   
  Yes            8/562             7/428         0.87 (0.31, 2.42)                         0.799                          0.91 (0.55, 1.52)     0.723
  No             3/536            27/813         0.17 (0.05, 0.56)                         0.001                          0.41 (0.23, 0.75)   **0.004**
  Smoking                                                                                                                                    
  Yes            9/712            18/669         0.47 (0.21, 1.05)                         0.079                          0.69 (0.46, 1.05)     0.081
  No             2/386            16/572         0.19 (0.04, 0.81)                         0.013                          0.43 (0.21, 0.91)   **0.026**

Adjusted for age, sex, drinking and smoking.

10.1371/journal.pone.0100055.t005

###### Stratified results for pri-miR-34b/c rs4938723 T\>C by age, sex, drinking and smoking.
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  Variable    CC vs. TT+TC   Crude OR (95% CI)           p           Adjust OR (95% CI)[a](#nt107){ref-type="table-fn"}           p          
  ---------- -------------- ------------------- ------------------- ---------------------------------------------------- ------------------- -----------
  Age                                                                                                                                        
  \<62           38/482           56/526         0.74 (0.48, 1.14)                         0.195                          0.86 (0.69, 1.07)     0.185
  ≥62            46/543           77/616         0.68 (0.46, 0.99)                         0.046                          0.79 (0.65, 0.96)   **0.016**
  Sex                                                                                                                                        
  Males          66/791           99/859         0.72 (0.52, 1.00)                         0.060                          0.84 (0.71, 0.99)   **0.033**
  Females        18/234           34/283         0.64 (0.35, 1.16)                         0.146                          0.75 (0.54, 1.03)     0.075
  Drinking                                                                                                                                   
  Yes            47/523           51/384         0.68 (0.45, 1.03)                         0.069                          0.81 (0.65, 1.01)     0.056
  No             37/502           82/758         0.68 (0.46, 1.02)                         0.063                          0.83 (0.67, 1.01)     0.062
  Smoking                                                                                                                                    
  Yes            58/663           78/609         0.68 (0.48, 0.98)                         0.038                          0.81 (0.68, 0.98)   **0.026**
  No             26/362           55/533         0.70 (0.43, 1.13)                         0.156                          0.83 (0.65, 1.06)     0.141

Adjusted for age, sex, drinking and smoking.

A significantly decreased risk of ESCC was observed with pri-miR-124-1 rs531564 GG genotype from [Table 4](#pone-0100055-t004){ref-type="table"} in patients who were older than 62 years (p = 0.010, OR = 0.52, 95% CI = 0.32--0.86), no drinking (p = 0.004, OR = 0.41, 95% CI = 0.23--0.75) or no smoking (p = 0.026, OR = 0.43, 95% CI = 0.21--0.91). Female patients with miR-124-1 rs531564 GG genotype were associated with a borderline statistically decreased ESCC risk (p = 0.051, OR = 0.36, 95% CI = 0.13--1.01).

As shown in [Table 5](#pone-0100055-t005){ref-type="table"}, significant associations between pri-miR-34b/c rs4938723 CC genotype and ESCC risks were found in the following subgroups, older than 62 years (p = 0.016, OR = 0.79, 95% CI = 0.65--0.96), males (p = 0.033, OR = 0.84, 95% CI = 0.71--0.99) and smokers (p = 0.026, OR = 0.81, 95% CI = 0.68--0.98). Drinkers and non-drinkers both showed a borderline statistically decreased ESCC risk (p = 0.056 and p = 0.062).

MDR Analyses to the ESCC Risk of Five SNP Sites and Non-genetic Factors {#s3c}
-----------------------------------------------------------------------

Using the MDR analysis and including these SNPs and non-genetic factors, the results were presented in [Table 6](#pone-0100055-t006){ref-type="table"}. We found that all models have significant test results (p≤0.05), and the three-factor model (smoking, drinking, gender) had a maximum cross-validation consistency (100%), a higher testing balanced accuracy and a minimum p-value in the significant test, which was the optimal model.

10.1371/journal.pone.0100055.t006

###### MDR analysis for the ESCC risk in genetic and non-genetic factors.
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  Model                             Testing Accuracy   Cross-Validation Consistency     p
  -------------------------------- ------------------ ------------------------------ --------
  Smoking                                0.5864                   10/10               0.0070
  Smoking Drinking                       0.5923                   10/10               0.0031
  Smoking Drinking Gender                0.5921                   10/10               0.0035
  mir-27 mir-218 mir-34 Drinking         0.5891                    5/10               0.0054

Discussion {#s4}
==========

In this study, we evaluated the association between five genetic variations in pri/pre-microRNA and the risk of ESCC in a Chinese population. We found that two SNPs, rs531564 in pri-miR-124-1 and rs4938723 in pri-miR-34b/c, were associated with a significant decreased risk of ESCC.

Recent research showed that the microRNA miR-124 might play an important role in tumorigenesis [@pone.0100055-Furuta1]. Some case-control studies have concentrated on the relationship between the rs531564 in pri-miR-124-1 polymorphism and the cancer risk, such as bladder cancer [@pone.0100055-Yang1] and esophageal cancer [@pone.0100055-Ye1] (mainly type is EADC). However, the relationship between pri-miR-124-1 rs531564 polymorphism and ESCC risk has not been reported till now.

In this case-control study, we found that the GG genotype of the pri-miR-124-1 rs531564 polymorphism is associated with significantly decreased ESCC risk in the recessive model. These results suggest that the GG genotype in rs531564 is a protective factor for ESCC in the Chinese population.

The molecular basis for this action remains unclear; however, Qi et al. [@pone.0100055-Qi1] suggested that the GG genotype changes the formation of a ring-shaped structure compared with the CC genotype on the secondary structure of pri-miR-124-1. They also found that mature miR-124 expression in the GG genotype is higher than that in the CC genotype. Moreover, Makeyev et al. [@pone.0100055-Makeyev1] showed that miR-124 directly targets polypyrimidine tract-binding protein 1 (PTBP1) mRNA, which encodes a global repressor of alternative pre-mRNA splicing in non-neuronal cells. Their research also indicated that miR-124 expression leads to a decrease in the endogenous PTBP1 protein level. Another study demonstrated that knockdown of PTBP1 expression by siRNA impairs the growth of ovarian tumor cells and diminishes their malignant potential [@pone.0100055-He1], indicating that overexpression of PTBP1 can be an important component of a multistep process of carcinogenesis.

These previous findings and the results of the present study characterize a potential mechanism of pri-miR-124-1 rs531564 in carcinogenesis as follows: First, the rs531564 GG genotype may promote the expression of miR-124, which is a cancer suppressor. Second, miR-124 may subsequently target PTBP1, which acts as an oncogene, and decrease its expression. These processes eventually lower the risk of ESCC.

We observe that pri-miR-124-1 rs531564 GG polymorphism has more significant effects on decreasing ESCC risks in subgroups of elderly persons, females, no drinking and no smoking people. These results indicate that sex, age, smoking and drinking can impact the effect of this SNP site in ESCC genesis. For example, as smoking and drinking are the main risk factors for ESCC, the effect of rs531564 GG type was no longer significant in smoking or drinking group of decreasing the ESCC risks. We noticed that one case-control study showed that rs531564 variant carriers have increased risks for esophageal cancer in Caucasian population [@pone.0100055-Ye1]. However, the amount of population and ethnicity in Ye's study are different from our research. These may be the main causes of the differences.

In this study, we also checked the relationship between pri-miR-34b/c rs4938723 C/T polymorphism and the ESCC risk. To our knowledge, this is the first study to investigate the association between this SNP site and the ESCC risk.

There are two miR-34 loci in human genomes, one encoding miR-34a and the other encoding miR-34b/c. Recently, several studies have shown that miR-34b/c may play an important role in tumorigenesis. Some studies have found that miR-34b/c were down-regulated in oral cancer [@pone.0100055-Kozaki1] and colorectal cancer [@pone.0100055-Toyota1].

The rs4938723 C/T polymorphism, located within the CpG island of pri-miR-34b/c, were reported to be associated with risks of many kinds of cancer. For example, this SNP site has been reported to be associated with an increased risk of hepatocellular carcinoma and nasopharyngeal carcinoma. These findings suggest that the C allele of pri-miR-34b/c rs4938723 may be a risk factor for the development of hepatocellular carcinoma [@pone.0100055-Xu1] and nasopharyngeal carcinoma [@pone.0100055-Li1].

However, in the current study, we found that in the recessive model, CC genotype of pri-miR-34b/c rs4938723 was associated with a significant decreased risk of ESCC. Several other studies have also examined the relationship between pri-miR-34b/c rs4938723 and the cancer risk, and obtained results similar to ours. For example, compared with the TT genotype, CC genotype of pri-miR-34b/c rs4938723 was found associated with a significant decreased risk of colorectal cancer. In another kind of tumor, intracranial aneurysm, they also observed similar results.

The possible reason for different results may be that the same variation in microRNA plays different roles in different types of cancers.

We also utilized the MDR analysis in order to explore the relation between the high-order multiple-factor interactions and the risk of ESCC. We found that smoking, drinking and sex were the main risk factors that can lead to ESCC. These results suggest that among the various factors, non-genetic factors, such as smoking and drinking, are the main factors that can lead to cancer risk. This result suggests that lifestyle plays an important role in carcinogenesis. This can also partly explain why there are differences between subgroups that have distinct smoking and drinking status in the stratified analysis.

In summary, our study examined the relationship between five SNPs in microRNA and ESCC risk. We finally found that GG genotype in pri-miR-124-1 and CC genotype in pri-miR-34b/c may decrease risks of ESCC in a Chinese population. These results suggest that some microRNAs may play an important role in ESCC genesis. Our findings enhance the current understanding of the mechanism of ESCC.
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